Shuttle Pharma Details $3.5M Public Offering with Deep Discount and Significant Dilution
SHPH is trading near its 52-week low of $0.8 (14% above the low) on light trading volume (0.1× avg).
Summary
Shuttle Pharmaceuticals Holdings, Inc. has filed an 8-K detailing the definitive agreements for its recently closed public offering, which raised approximately $3.5 million through the sale of common stock and pre-funded warrants.
Key Events · Financing and Capital Events · SHPH
-
Public Offering Details Finalized
The company entered into definitive agreements for a public offering that closed on March 9, 2026, raising approximately $3.5 million. This follows the 424B3 filing on March 9, 2026, which finalized the terms of this offering.
-
Significant Dilution
The offering involved the sale of 2,238,800 common shares and 4,761,200 pre-funded warrants, representing a substantial increase in potential outstanding shares relative to the company's market capitalization.
-
Deep Discount Pricing
Common stock was priced at $0.50 per share and pre-funded warrants at $0.499, a significant discount compared to the current stock price of $0.91.
-
Use of Proceeds
Up to $1.5 million of the net proceeds are designated for marketing efforts, with the remainder for general corporate purposes and working capital.
Analysis · SHPH · Life Sciences
This 8-K provides the contractual details of a public offering that closed on March 9, 2026, and was previously finalized in a 424B3 filing. The offering raised approximately $3.5 million, a substantial amount relative to the company's current market capitalization of $2.88 million, indicating significant dilution for existing shareholders. The offering included 2,238,800 shares of common stock and 4,761,200 pre-funded warrants, with the common stock priced at $0.50 per share and pre-funded warrants at $0.499, representing a deep discount to the current stock price of $0.91. While highly dilutive, this capital raise is critical for the micro-cap company's operations, with proceeds allocated to marketing efforts and general corporate purposes. The 30-day lock-up for executive officers and directors provides a temporary buffer against immediate insider selling.
At the time of this filing, SHPH was trading at $0.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9M. The 52-week trading range was $0.80 to $13.63. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.